Antitumour activity of Salmonella typhimurium VNP20047 in B16(F10) murine melanoma model.

Joanna Jazowiecka-Rakus; Stanisław Szala

doi:10.18388/abp.2004_3569

Antitumour activity of Salmonella typhimurium VNP20047 in B16(F10) murine melanoma model.

Joanna Jazowiecka-Rakus Department of Molecular Biology, Centre of Oncology, Maria Skłodowska-CurieMemorial Institute, Gliwice, Poland. jjazowiecka@io.gliwice.pl;
Stanisław Szala

DOI: https://doi.org/10.18388/abp.2004_3569

Abstract

A tumour therapy is proposed based on attenuated Salmonella typhimurium VNP20047 expressing the Escherichia coli cytosine deaminase gene. VNP20047 was administered intravenously to B16(F10) melanoma-bearing C57BL/6 mice. VNP20047 proliferated within tumours and livers regardless of the initial inoculum dose. After 10 days the number of bacteria increased in livers up to 4.2 x 10(6) cfu/g and decreased in tumours down to 5.9 x 10(6) cfu/g. VNP20047 at 1 x 10(5) cfu/mouse, when combined with 5-fluorocytosine, inhibited tumour growth by 85% without prolonging animal survival. Histology studies revealed severe lesions in tumours and livers. These data suggest that S. typhimurium VNP20047 induced inflammatory responses, even though the strain was attenuated.

Published

2004-09-30

Issue

Vol. 51 No. 3 (2004)

Section

Articles

Acta Biochimica Polonica is an OpenAccess quarterly and publishes four issues a year. All contents are distributed under the Creative Commons Attribution-ShareAlike 4.0 International (CC BY 4.0) license. Everybody may use the content following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.